title: Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.
abstract: OBJECTIVE
  Biosimilar filgrastim was compared with lenograstim for autologous haematopoietic stem-cell transplant (HSCT) in patients with haematological malignancies. Data from a separate group of sibling donors who underwent allogeneic HSCT are also reported.
  
  
  METHODS
  Patients with lymphoma or multiple myeloma (MM) who underwent autologous HSCT with biosimilar filgrastim were compared with a historical control group of patients who received lenograstim. Peripheral blood (PB) cells counts were monitored after 7-8 consecutive days of granulocyte-colony stimulating factor (G-CSF) injection and apheresis was performed on day 8 if PB CD34+ cell count was ⩾10 cells/µl. The target PB CD34+ cell doses were ⩾2.0 × 10(6)/kg (lymphoma), ⩾4.0 × 10(6)/kg (MM ⩾60 years old) or ⩾8.0 × 10(6)/kg (MM <60 years old).
  
  
  RESULTS
  A total of 259 patients were included in the autologous HSCT comparison (biosimilar filgrastim, n = 104; lenograstim, n = 155). In patients with lymphoma and older MM patients (⩾60 years old), no significant differences were observed between groups with regard to stem-cell mobilization parameters. However, in MM patients <60 years old, all parameters were significantly superior in the biosimilar filgrastim group, including the need for 1 rather than 2 apheresis procedures. No significant differences were observed between groups in median number of days to absolute neutrophil count (ANC) or platelet recovery. In the allogeneic setting, 47 sibling donors received biosimilar filgrastim. Mean CD34+ count at the first apheresis was 6.1 × 10(6)/kg. A total of 13 donors needed a second apheresis and 4 required a third. Among recipients, median days to ANC recovery was 16 (10-28) and to platelet recovery was 13 (9-54).
  
  
  CONCLUSIONS
  Biosimilar filgrastim is as effective as lenograstim for autologous HSCT in patients with lymphoma or MM patients ⩾60 years old. However, mobilization with biosimilar filgrastim appeared to be superior to that with lenograstim in younger MM patients.
authors.affiliation: Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
authors.forename: Shab
authors.initials: S
authors.lastname: Uddin
authors.affiliation: Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
authors.forename: Pippa
authors.initials: P
authors.lastname: Russell
authors.affiliation: Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
authors.forename: Maresa
authors.initials: M
authors.lastname: Farrell
authors.affiliation: Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
authors.forename: Barbara
authors.initials: B
authors.lastname: Davy
authors.affiliation: Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
authors.forename: Joe
authors.initials: J
authors.lastname: Taylor
authors.affiliation: Barts Health NHS Trust and Blizard Institute, Queen Mary University of London, Division of Haemato-Oncology, St Bartholomew's Hospital, London EC1A 7BE, UK.
authors.forename: Samir G
authors.initials: SG
authors.lastname: Agrawal
keywords: G-CSF; biosimilar; filgrastim; haematopoietic stem-cell transplant; lenograstim
references.citation: Microb Cell Fact. 2008 Apr 04;7:13
references.pmid: 18394164
references.citation: Leukemia. 2011 Jan;25(1):1-6
references.pmid: 21224858
references.citation: Br J Haematol. 2005 Sep;130(5):740-6
references.pmid: 16115131
references.citation: Support Care Cancer. 2013 Oct;21(10):2925-32
references.pmid: 23903799
references.citation: Transfusion. 2015 Feb;55(2):430-9
references.pmid: 24965197
references.citation: Transfusion. 2014 Aug;54(8):2028-33
references.pmid: 24588265
references.citation: Bone Marrow Transplant. 2001 Aug;28(3):259-64
references.pmid: 11535993
references.citation: Eur J Cancer. 1994;30A Suppl 3:S12-4
references.pmid: 7535065
references.citation: Int J Clin Pharmacol Ther. 2011 Aug;49(8):510-8
references.pmid: 21781651
references.citation: Cytokine. 1997 May;9(5):360-9
references.pmid: 9195136
references.citation: Haematologica. 1999 Jun;84(6):493-8
references.pmid: 10366791
references.citation: BioDrugs. 2010 Dec 1;24(6):347-57
references.pmid: 20873878
references.citation: Adv Ther. 2014 Apr;31(4):451-60
references.pmid: 24687301
references.citation: Transfusion. 2013 Dec;53(12):3240-2
references.pmid: 23489237
references.citation: Theranostics. 2014 Jan 23;4(3):280-9
references.pmid: 24505236
references.citation: Bone Marrow Transplant. 2000 May;25(9):931-5
references.pmid: 10800059
references.citation: J Biol Chem. 1990 Jul 15;265(20):11432-5
references.pmid: 1694845
references.citation: Transfus Apher Sci. 2013 Jun;48(3):315-20
references.pmid: 23611684
references.citation: Bone Marrow Transplant. 2010 May;45(5):832-8
references.pmid: 20173787
references.citation: Biochemistry. 1996 Jun 11;35(23):7299-307
references.pmid: 8652506
references.citation: Curr Med Res Opin. 2003;19(8):753-9
references.pmid: 14687447
references.citation: Eur J Haematol. 1997 Sep;59(3):177-83
references.pmid: 9310126
references.citation: Am J Hematol. 2008 Aug;83(8):644-8
references.pmid: 18508321
references.citation: Adv Ther. 2011 Apr;28(4):304-10
references.pmid: 21400232
references.citation: Clin Pharmacol Ther. 2013 Apr;93(4):315-7
references.pmid: 23443756
references.citation: J Cancer Res Clin Oncol. 2005 Mar;131(3):152-6
references.pmid: 15583936
references.citation: Leuk Lymphoma. 1999 Nov;35(5-6):501-5
references.pmid: 10609787
references.citation: Br J Haematol. 2006 Sep;134(5):517-25
references.pmid: 17018030
references.citation: Leuk Lymphoma. 2014 Jan;55(1):74-7
references.pmid: 23566160
references.citation: Ann Oncol. 2010 Jul;21(7):1419-29
references.pmid: 20019087
references.citation: Clin Exp Med. 2015 May;15(2):145-50
references.pmid: 24722996
references.citation: Ecancermedicalscience. 2013 Jun 25;7:327
references.pmid: 23818939
references.citation: Bone Marrow Transplant. 2013 Jul;48(7):922-5
references.pmid: 23318540